Brain extract was used as a positive control.
However, when PtdIns4 P purified from brain extract was used as a substrate, we observed the production of radiolabelled PtdIns 3,5) P2, suggesting that some PtdIns3 P was present in the samples, since the procedure used to purify PtdIns4 P from the brain does not preclude contamination with other PtdInsPs.
The αS levels in brain extracts were measured using a sandwich ELISA.
To determine whether fluoxetine treatment leads to increased expression of pro-inflammatory markers, mice were treated with fluoxetine, and brain extracts were analyzed using real-time PCR and multiplex ELISA.
Thus, an extract enriched with CS-bearing PGs was purified from whole mouse brain and this extract was used to perform a solid-phase binding assay with various forms of Aβ (Fig. 2a and b).
RNA samples from brain extracts were hybridized overnight using two different tags on a μParaflo microfluidic chip using a microcirculation pump developed by Atactic Technologies (Houston, TX). mRNA microarray hybridization was done as described previously[ 19].
RNA samples from liver and brain extracts were hybridized overnight using two different tags on a μParaflo microfluidic chip using a microcirculation pump developed by Atactic Technologies (Houston, TX) (Gao et al. 2004).
Whole brain extracts were then examined using either high-field 1H NMR spectroscopy or HPLC.
In addition, brain extracts are often used to validate and complement the in vivo H-[C] NMR results.
Brain extracts were acidified and derivitized using O-phenylenediamine, separated by HPLC using a CB18B 'Econosphere' column (150 × 4.6 mm ID, 3 m) from Alltech (Deerfield, IL, USA) and detected with fluorescence by excitation and 350 nm and absorbance at 410 nm.
